52 high profile inmates now negative of COVID-19 | Inquirer News

52 high profile inmates now negative of COVID-19

/ 08:40 PM November 11, 2020

MANILA, Philippines— The 52 persons deprived of liberty (PDL) or high profile inmates from Building 14 are now negative of COVID-19, an official from the Bureau of Corrections (BuCor) said Wednesday.

“They are all negative sa COVID-19,” BuCor Spokesman Gabriel Chaclag told reporters at the Kapihan sa Manila Bay.

The 52 inmates are from Building 14, the most secure area of Bilibid’s Maximum Security Compound. It houses high profile inmates, mostly convicted of drugs.

Article continues after this advertisement

However, Chaclag said that some of the inmates would remain segregated as advised by the doctors because some have mild symptoms.

FEATURED STORIES

He said the inmates will eventually return to Building 14 once the doctors have given their go signal.

RELATED STORY

52 more high-profile inmates in Bilibid test positive for COVID-19

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: Bilibid, COVID-19, swab test

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.